Stock Ratings / Health Care / RNAZ / forecast

RMTI (28) BCTX (41) NXTC (48) CPHI (45) ⌘ Pro Terminal →

TransCode Therapeutics Inc. (RNAZ) 12-Month Stock Forecast & Price Target Cone

$1.73 -0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.72

TransCode Therapeutics Inc. (RNAZ) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $29.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.72 (-0.29%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNAZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY RNAZ SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (32% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.86-8.6% Next Q

Q2 (-2Q)

Grade C-$1.70+4.1% Next Q

Q3 (-1Q)

Grade C-$1.77-2.3% Next Q

Current

Grade D$1.73-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNAZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNAZ currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($1.82) forces dealer call-delta covering toward $13.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNAZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RNAZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RNAZ Position Size: $10,000

Shares at $1.73: 5780.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.28

$7,399

$-2,601 (-26.0%)

12M Consensus BaseTarget $1.64

$9,480

$-520 (-5.2%)

12M Bull Case BreakoutTarget $13.23

$76,474

+$66,474 (+664.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$12	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNAZ)

✓Walkthrough of RNAZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RNAZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.40%▲ RESISTANCE BREAKOUT

2026-10-30O $1.73H $1.78L $1.62C $1.73VOL 16.1K

RES: $1.20SUP: $0.58SMA50: $1.83SMA200: $6.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNAZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNAZ Butterfly Map → + Track RNAZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNAZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNAZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RNAZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNAZ)

Health Care Rank #422 of 1016 ⚔️ RMTI vs RNAZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNAZ vs. RMTI, BCTX, NXTC, CPHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TransCode Therapeutics Inc. (RNAZ) ranks #422 by composite RQD confidence (47/100, grade D) and #807 by equity capitalization ($29.3M). Within this direct 5-issuer industry benchmark cohort, RNAZ leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RNAZ at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RNAZ ACTIVE TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	Benchmark Subject
RMTI Rockwell Medical Inc.	E	28/100	—	16.9%	-10.6%	0.00%	$29.5M	/rmti-vs-rnaz →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-rnaz →
NXTC NextCure Inc.	D	48/100	—	—	-35.0%	+2.92%	$29.9M	/nxtc-vs-rnaz →
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-rnaz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001829635

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TransCode Therapeutics Inc. (RNAZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.7M, operating cash flow of -$19.5M, and free cash flow of -$19.5M (-46.2% YoY). On the balance sheet, RNAZ closed FY2025 with $162.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$34.7M	-$19.5M	-$19.5M	$162.4M	—
FY2024 (FY)	2024-12-31	$0	-$16.8M	-$13.3M	-$13.4M	$7.3M	—
FY2023 (FY)	2023-12-31	$0	-$18.5M	-$18.1M	-$18.1M	—	—

3. RNAZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNAZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, TransCode Therapeutics Inc. (NASDAQ: RNAZ) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.73 (-0.57% 1D, market cap $29.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RNAZ ranks #422 in composite RQD confidence.

How does RNAZ compare to RMTI and BCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAZ carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RMTI (Rockwell Medical Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -10.6%, cap $29.5M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $28.9M). Among the 5-stock peer group, RNAZ leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNAZ?

Per RNAZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001829635), TransCode Therapeutics Inc. generated $0 in revenue, -$34.7M in net income, and -$19.5M in free cash flow against $162.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNAZ trading relative to its 50-day, 200-day, and 52-week technical levels?

RNAZ last traded at $1.73 (-0.57% on volume of 40,841 shares), positioning the stock -5.46% below its 50-day simple moving average ($1.83) and -71.87% below its 200-day simple moving average ($6.15). Across its 52-week range of $1.52 to $12.60, RNAZ sits at the 1.9% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.51 to $1.95).

RNAZ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RNAZ's 12-month stock price target?

TransCode Therapeutics Inc. (RNAZ) carries a 12-month consensus base price target of $1.64 (-5.2% from $1.73), with a bull-case target of $13.23 and a bear-case floor of $1.28.

Is RNAZ stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates RNAZ D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: RNAZ RQD Cockpit RNAZ 12M Forecast RNAZ Earnings & Move RNAZ Dividends & DRIP RNAZ Insiders & 13F RNAZ Whale Options RNAZ Profit Sankey RNAZ News & Why